Table 3.
Standardized mortality ratio (SMR) among 2-year survivors of allogeneic HCT
| Variables | Entire cohort |
Standard risk of relapse |
High risk of relapse |
|||
|---|---|---|---|---|---|---|
| No. of deaths | SMR (95% CI) | No. of deaths | SMR (95% CI) | No. of deaths | SMR (95% CI) | |
| All patients | 241 | 9.9 (8.7-11.2) | 152 | 8.4 (7.1-9.8) | 88 | 14.5 (11.7-17.7) |
| Sex | ||||||
| Male | 147 | 8.2 (6.9-9.6) | 97 | 7.4 (6.0-8.9) | 50 | 10.8 (8.0-14.0) |
| Female | 94 | 12.8 (10.3-15.5) | 55 | 9.9 (7.4-12.6) | 38 | 21.5 (15.2-28.9) |
| Age at transplantation, y | ||||||
| Younger than 18 | 63 | 16.5 (12.7-20.8) | 48 | 14.6 (10.8-19.0) | 15 | 28.8 (16.1-45.3) |
| 18 to 45 | 150 | 9.1 (7.7-10.6) | 92 | 7.7 (6.2-9.3) | 57 | 12.9 (9.8-16.5) |
| Older than 45 | 28 | 7.1 (4.7-9.9) | 12 | 4.2 (2.2-7.0) | 16 | 14.2 (8.1-22.0) |
| Year of transplantation | ||||||
| 1974 to 1979 | 15 | 9.4 (5.2-14.7) | 13 | 9.4 (5.0-15.3) | 2 | 13.4 (1.3-38.5) |
| 1980 to 1984 | 49 | 7.9 (5.8-10.2) | 34 | 7.4 (5.1-10.1) | 15 | 9.2 (5.1-14.5) |
| 1985 to 1989 | 63 | 10.5 (8.1-13.3) | 39 | 8.9 (6.3-11.9) | 24 | 15.0 (9.6-21.6) |
| 1990 to 1994 | 71 | 11.2 (8.7-13.9) | 49 | 10.2 (7.5-13.2) | 21 | 13.8 (8.5-20.3) |
| 1995 to 1998 | 43 | 10.5 (7.6-13.8) | 17 | 5.8 (3.4-8.9) | 26 | 22.5 (14.7-31.9) |
| Survival after diagnosis | ||||||
| 2 to 5 y | 149 | 77.5 (65.6-90.5) | 92 | 73.5 (59.2-89.3) | 57 | 85.0 (64.4-108.5) |
| 6 to 10 y | 50 | 8.3 (6.1-10.7) | 29 | 6.3 (4.2-8.8) | 20 | 13.9 (8.5-20.7) |
| 11 to 15 y | 21 | 3.7 (2.3-5.4) | 15 | 3.7 (2.0-5.7) | 6 | 3.6 (1.3-7.2) |
| 16 to 20 y | 20 | 2.9 (1.8-4.3) | 15 | 3.0 (1.7-4.8) | 5 | 2.5 (0.8-5.2) |
| 21+ y | 1 | 0.3 (0.0001-1.1) | 1 | 0.3 (0.0001-1.2) | 0 | — |
| Chronic graft-versus-host disease | ||||||
| Yes | 158 | 12.4 (10.5-14.4) | 95 | 10.6 (8.6-12.9) | 62 | 16.8 (12.8-21.2) |
| No | 78 | 6.9 (5.4-8.5) | 53 | 5.9 (4.4-7.6) | 25 | 10.6 (6.9-15.2) |
| Primary diagnosis | ||||||
| AML | 82 | 10.8 (8.6-13.3) | 46 | 8.5 (6.2-11.1) | 36 | 17.3 (12.1-23.5) |
| CML | 74 | 8.2 (6.4-10.2) | 41 | 6.8 (4.9-9.1) | 33 | 11.0 (7.6-15.0) |
| ALL | 46 | 12.8 (9.4-16.8) | 32 | 10.9 (7.5-15.1) | 14 | 21.0 (11.5-33.5) |
| NHL | 10 | 12.5 (6.0-21.5) | 4 | 8.5 (2.2-18.9) | 5 | 16.1 (5.1-33.4) |
| SAA | 17 | 5.7 (3.3-8.8) | 17 | 5.7 (3.3-8.8) | 0 | — |
| IEM | 12 | 36.7 (18.9-60.4) | 12 | 36.7 (18.9-60.4) | 0 | — |
SMR indicates standardized mortality ratio; 95% CI, 95% confidence interval; and —, not applicable.
†
One subject with unknown disease status at the time of HCT was excluded from the analysis.
‡
One subject with unknown cGVHD status was excluded from the analysis.